Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 and SOX Chemotherapy in Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
NCT07315854Phase 2Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Beijing Friendship Hospital. Started Nov 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07315854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07315854.